(Q53664722)

English

Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.

scientific article published on 19 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 May 2018

http://europepmc.org/abstract/MED/22329377

Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 May 2018

http://europepmc.org/abstract/MED/22329377

1 reference

based on heuristic

inferred from title

chronic hepatitis B

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

R Idilman

1

1 reference

Europe PubMed Central

PubMed publication ID

17 May 2018

http://europepmc.org/abstract/MED/22329377

K Cinar

2

1 reference

Europe PubMed Central

PubMed publication ID

17 May 2018

http://europepmc.org/abstract/MED/22329377

G Seven

3

1 reference

Europe PubMed Central

PubMed publication ID

17 May 2018

http://europepmc.org/abstract/MED/22329377

Y Bozkus

4

1 reference

Europe PubMed Central

PubMed publication ID

17 May 2018

http://europepmc.org/abstract/MED/22329377

A Elhan

5

1 reference

Europe PubMed Central

PubMed publication ID

17 May 2018

http://europepmc.org/abstract/MED/22329377

M Bozdayi

6

1 reference

Europe PubMed Central

PubMed publication ID

17 May 2018

http://europepmc.org/abstract/MED/22329377

C Yurdaydin

7

1 reference

Europe PubMed Central

PubMed publication ID

17 May 2018

http://europepmc.org/abstract/MED/22329377

K Bahar

8

1 reference

Europe PubMed Central

PubMed publication ID

17 May 2018

http://europepmc.org/abstract/MED/22329377

publication date

19 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

17 May 2018

http://europepmc.org/abstract/MED/22329377

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

17 May 2018

http://europepmc.org/abstract/MED/22329377

19

1 reference

Europe PubMed Central

PubMed publication ID

17 May 2018

http://europepmc.org/abstract/MED/22329377

3

1 reference

Europe PubMed Central

PubMed publication ID

17 May 2018

http://europepmc.org/abstract/MED/22329377

220-226

1 reference

Europe PubMed Central

PubMed publication ID

17 May 2018

http://europepmc.org/abstract/MED/22329377

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Surrogate end points and long-term outcome in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Natural history of chronic hepatitis B virus infection and long-term outcome under treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Prevention by Lamivudine of hepatocellular carcinoma in patients infected with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Hepatitis B virus resistance to nucleos(t)ide analogues.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2011.01542.X

21 January 2018

Identifiers

10.1111/J.1365-2893.2011.01542.X

1 reference

Europe PubMed Central

PubMed publication ID

17 May 2018

http://europepmc.org/abstract/MED/22329377

release_zm7femtxsrg5hpq3jczpgl4y4i

1 reference

https://api.fatcat.wiki/v0/release/zm7femtxsrg5hpq3jczpgl4y4i

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 May 2018

http://europepmc.org/abstract/MED/22329377

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53664722&oldid=2070976091"